Strainsforpains, Inc. corporate update

Strainsforpains announces closing out 2023 with its largest orders to date. End Quote

New York, NY (1888PressRelease) January 12, 2024 - Strainsforpains, Inc. secures its largest orders to date from NYC establishments.

Strainsforpains, Inc. Announces Corporate Update (NY, NY)-(January 11, 2024)-(Strainsforpains, Inc.)(OTC Markets : EBYH).

Strainsforpains, Inc. is pleased to announce it has closed out 2023 with its largest orders to date, valued at $65,000, from various CBD and health markets, including Forces of Nature, Portokali, and other prominent establishments in New York City. This significant achievement marks a major milestone for our company and underscores the increasing demand for Strainsforpains’ high-quality products. With this significant order, Strainsforpains will deliver its full spectrum products, renowned for their exceptional quality and effectiveness. The company continues its collaboration with Popped, a NYC company, to jointly develop products and services with anticipated sales of six hundred thousand dollars by the end of 2024.

With a commitment to meeting the growing demand for its signature brand and product line, Strainsforpains has ambitious plans for 2024. Our other CBD product line will feature water-soluble liposomal technology, an innovative nanoliposmal encapsulation that has been scientifically proven to increase the absorption of CBD by 80%. This cutting-edge technology distinguishes our products in the market, offering superior benefits to our clients. By diversifying its product offerings, the company aims to cater to a broader range of customer needs and solidify its position in the industry.

The data technology division, which collaborates with hospitals and physicians, is also expected to experience a substantial increase in sales in 2024. Our app is currently being upgraded to position itself as a leading educational tool for pain management operations at hospitals and with doctors specializing in pain relief. The company collaborates with NYU, Teva Pharmaceuticals, and other major US and international Mr. Shainberg, president of Strainsforpains, expressed his satisfaction, stating “We are thrilled to conclude 2023 with our most substantial orders to date and anticipate an outstanding 2024, as we introduce our signature brand and product line to the market”. This order consists of a cream- based product, designed for pain relief related to muscle pain and bone ailments. It positions Strainsforpains to make a significant impact in the CBD industry and establish itself as a leader in effective pain relief solutions. The projected market demand for Strainsforpains’ signature brand and product line is highly promising.

l organizations to share data. Poised for swift growth and success, Strainsforpains is embarking on its journey to offer a compelling range of products and services. The company acknowledges the powerful synergy between telehealth platforms and high-quality pain relief products, laying the foundation for a promising venture ahead.

To meet the expected demand in 2024, Strainsforpains plans to increase production capacity. The ongoing rehabilitation of its 6-acre facility in Pennsylvania will enable potential use for manufacturing and distribution in the event of a significant increase in demand. This strategic move aims to scale up operations without compromising product quality.

Strainsforpains has conducted extensive market research and analysis to support our optimistic projections for 2024. The CBD and THC market is constantly growing, with consumers increasingly seeking high-quality and unique products. Our commitment to innovation, superior quality, and customer satisfaction positions us well to capitalize on this market trend and drive substantial growth in the coming year.

In summary, Strainsforpains, Inc. is delighted to announce the successful culmination of its largest orders to date, secured from establishments based in New York City. This accomplishment stands as a testament to the trust and confidence that our customers place in our products. Leveraging our full spectrum offerings, our cutting-edge water-soluble liposomal technology, and our data technology, we are strategically positioned to play a pivotal role in the dynamic CBD industry, poised for substantial growth in the upcoming year.

Overview of Strainsforpains, Inc.: Please visit our website at http://www.strainsforpains.com/. Strainsforpains, Inc. is an innovative healthcare data technology Company located in New York, N.Y. The Company's objectives are to provide doctors, nurses, dispensaries, and patients access to an APP that will allow for an advanced determination of comparison of strains or brands of cannabis combinations with major illnesses, in a user-friendly manner. The company owns a 6.5-acre facility in Pennsylvania that will be used for CBD product production. Mr. Shainberg is a member of the prestigious International Cannabinoid Research Society.

About International Cannabinoid Research Society. The organization is dedicated to scientific research of cannabinoids. It has 1300 research scientists among its members.

About Teva. Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global leader in generic and innovative medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take Teva medicine every day and are served by one of the largest and most complex supply chains in the pharmaceutical industry.

Safe Harbor Statement: Statements in this press release that are not historical fact may be deemed forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although Strainsforpains, Inc. believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, Strainsforpains, Inc. is unable to give any assurance that its expectations will be attained. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Strainsforpains, Inc.'s ability to control, and those actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is and will be included in Strainsforpains, Inc. filings with the Securities and Exchange Commission and OTC Markets. For further info and Media Contact: Y. S. Shainberg, Strainsforpains, Inc. strainsforpains ( @ ) gmail dot com, 347-218-0844. Sean Goodwin: Sean.strainsforpains ( @ ) gmail dot com

###

space

Other Related Press Releases